Program
sutezolid
Also written as “PNU-100480”, “BIA 5-1058 and Furosemide” and “Treatment C”.
Its studies are mostly in Tuberculosis · Pulmonary Arterial Hypertension · Diabetes Mellitus, Type 2, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sequella | 30 open or running | phase 2since Oct 19, 2010 | Mar 27, 2009 | none ahead |
| AJU Pharm | 10 open or running | phase 1since Jul 12, 2021 | Jul 12, 2021 | none ahead |
| Bial - Portela C | 10 open or running | phase 1since Sep 8, 2025 | Sep 8, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 27, 2009First study: phase 1 study in TuberculosisNew to SequellaSequella · NCT00871949 · 19 enrolled · United States
- Oct 6, 2009Phase 1 study in TuberculosisSequella · NCT00990990 · 59 enrolled · United States
- Oct 19, 2010Phase 2 study in TuberculosisSequella · NCT01225640 · 59 enrolled · South Africa
- Jul 12, 2021AJU Pharm's first study: phase 1 study in Diabetes Mellitus, Type 2New to AJU PharmAJU Pharm · NCT04970940 · 30 enrolled · Korea, Republic of
- Sep 8, 2025Bial - Portela C's first study: phase 1 study in Pulmonary Arterial HypertensionNew to Bial - Portela CBial - Portela C · NCT07173738 · 44 enrolled · United Kingdom
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“70S ribosome inhibitor”ChEMBL 37, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07173738Pulmonary Arterial Hypertension · United Kingdom | 1 | Completed | Bial - Portela C | Sep 7, 2018 | 44 |
| NCT04970940Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | AJU Pharm | Oct 7, 2020 | 30 |
| NCT01225640Tuberculosis · South Africa | 2 | Completed | Sequella | Dec 2011 | 59 |
| NCT00990990Tuberculosis · United States | 1 | Completed | Sequella | May 2010 | 59 |
| NCT00871949Tuberculosis · United States | 1 | Completed | Sequella | Aug 2009 | 19 |
How it is read
Names in the registry
- “PNU-100480”, 23 entries
- “BIA 5-1058 and Furosemide”, 1 entry
- “Treatment C”, 1 entry
Conditions, from the studies’ own filings
- Tuberculosis, 3 studies
- Pulmonary Arterial Hypertension, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.